Personalised LADD immunotherapy - Aduro BioTech

Drug Profile

Personalised LADD immunotherapy - Aduro BioTech

Alternative Names: pLADD

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aduro BioTech
  • Class Antineoplastics; Attenuated vaccines; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 02 May 2017 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03189030)
  • 19 Jan 2017 Pharmacodynamics data from a preclinical studies in Cancer released by Aduro BioTech
  • 19 Jan 2017 Aduro Biotech in-licenses neoantigen identification technology from Stanford University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top